Navigation Links
Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Date:1/17/2008

RIDGEFIELD, Conn., Jan. 17 /PRNewswire/ -- Boehringer Ingelheim announced today that enrollment is complete for the landmark RE-LY trial to evaluate the long-term efficacy and safety of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation. RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in 1,000 centers in 44 countries worldwide enrolled between December 2005 and December 2007. Currently, more than 10,000 patients have been treated for at least 6 months with final study results expected to be reported in early 2009.

The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke. Currently, the standard treatment to prevent stroke in these patients is the vitamin K antagonist, warfarin. It is estimated that warfarin is currently prescribed for only half of all eligible patients.

Dr. Salim Yusuf, Professor of Epidemiology and Cardiology and head of the study coordinating center at McMaster University in Hamilton, Canada, stated that: "Patient enrollment in RE-LY has exceeded our original expectations by far."

Atrial fibrillation is the most common sustained cardiac rhythm disturbance affecting six percent of individuals over the age of 65 and 10 percent of people over the age of 80. Atrial fibrillation is a leading risk factor for stroke and, despite warfarin sodium being available as an effective treatment option, atrial fibrillation still accounts for approximately 15 percent of all strokes.

Approximately 750,000 Americans suffer a stroke each year. More than 150,000 of these strokes are fatal, making it the third leading cause of death in the United States. Approxima
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... present at the Sixth Annual JMP Securities Healthcare Conference on ... a.m. Pacific Time) at The St. Regis New York Hotel ... Executive Officer, is scheduled to provide a corporate overview. ...
... MINNEAPOLIS, Sept. 21, 2011 Uroplasty, Inc. (NASDAQ: ... markets innovative proprietary products to treat voiding dysfunctions, announced today ... President and CFO, will present the Company,s business strategy and ... at 2:30 PM ET on Tuesday, September 27, 2011 at ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 3Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2
(Date:9/16/2014)... News) -- One in five American men admits ... a new survey shows. A nationally representative ... such violence is more prevalent than diabetes. This ... slapping and hitting, kicking, biting, choking, burning or ... said. Although abuse by high-profile professional athletes ...
(Date:9/16/2014)... School of Medicine researcher Dr. Jeffrey Samet and ... recently awarded a five year, $5 million grant ... their project titled: Improving Physician Opioid Prescribing for ... are the second most commonly abused substances in ... to prescription opioids now exceed deaths from motor ...
(Date:9/16/2014)... Since the adoption of pediatric legislation, ... in line with increased investment in R&D for pediatric ... novel paediatric information and more than 130 products have ... there has been 221 changes relating to the efficacy ... old or new trials in children and 89 additions ...
(Date:9/16/2014)... testing ground, researchers at Johns Hopkins have shown that ... can substantially reduce patient wait times and possibly improve ... report on the pilot study, published online Sept. 9, ... so-called "Just-in-Time" training and inventory process used now by ... keep complicated operations from bottlenecking. , "We realized that ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 RxAnte, ... predictive analytics and targeted clinical programs, today announced ... changes support the Company’s drive to improve medication ... targeted clinical programs. On September 2, 2014, Brock ... Millennium Health, announced that RxAnte founder and President ...
Breaking Medicine News(10 mins):Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3
... Rao, an American scientist of Indian origin has been ... a new system which makes use of data for ... is the Senior Director of Engineering Research Development at ... ,Rao is reported to have contributed towards ...
... drinkers go in for wholesome and healthy food, beer drinkers ... also seen among// wine drinkers when compared to beer ... in Copenhagen have found that beer drinkers buy unhealthy food ... prefer wine, according to BBC News. ,Studying ...
... Jefferson and colleagues from Cochrane Collaboration (International private organization ... trials) reviewed data from over 50 clinical trials involving ... researchers found that the old drugs which were used ... some drugs like amantadine and rimantidine which were used ...
... employ people with Asperger's Syndrome, who suffer from difficulties ... total of 50,000 people who suffer from this disorder, ... //People who suffer from the Asperger's Syndrome have difficulty ... though the intelligence of those who suffer from this ...
... Researchers from McMaster University has reported in the Journal ... found that the scientists screened 480 strains of Streptomyces ... all the strains were multi-drug resistance //as they were ... antibiotics. ,The researchers were astonished by ...
... transmission case is due today in Harbin court today. The ... blood collected from an infected couple who sold their blood ... Northeast China. // It was found that 15 people were ... and the other four got infection indirectly from the infected, ...
Cached Medicine News:
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: